๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Cervicogenic Headache
NCT07347730Myofascial Trigger Points, Cervicogenic Headache, Dorsal Root Ganglion
Beijing Tiantan Hospital
Not applicable
1,036
Beijing
2025-12-01
Recruiting
A Trial of Shengmai Liquid for Long COVID Fatigue.
NCT06980636Long COVID Fatigue
Beijing University of Chinese Medicine
Phase 4
100
Beijing
2025-12-01
Recruiting
Eye-Brain-Kidney in CKD
NCT07358572Chronic Kidney Diseases
Beijing Friendship Hospital
Observational
1,500
Beijing
2025-12-01
Recruiting
Safety and Tolerability Study of a Novel Bioartificial Liver in Liver Failure and Small-for-Size Syndrome
NCT07312864Liver Failure, Small-for-Size Syndrome
Beijing Friendship Hospital
Phase 1/2
12
Beijing
2025-12-01
Not yet open
Efficacy and Safety Evaluation of Non-invasive Temporal Interference Stimulation for Blood Pressure Regulation
NCT07239492Hypertension, Hypotension
Xuanwu Hospital, Beijing
Not applicable
25
Beijing
2025-12-01
Not yet open
Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer
NCT07238959Benign Prostate Hypertrophy(BPH), Prostate Cancer (Diagnosis), Prostate Neoplasm
Shanghai Changzheng Hospital
Observational
1,100
Beijing, Guangzhou, Nanjing, Suzhou, Shanghai, Chengdu, Ningbo
2025-12
Not yet open
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors
NCT07291050Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
40
Beijing
2025-12
Recruiting
A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.
NCT07230483Atopic Dermatitis (AD)
Keymed Biosciences Co.Ltd
Phase 2
246
Beijing
2025-12
Recruiting
TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors
NCT07266298Solid Metastatic Tumor
Neowise Biotechnology
Phase 1
24
Beijing
2025-12
Not yet open
Transcranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease II (TRANSFORM-AD II)
NCT07230158Alzheimer Disease
Xuanwu Hospital, Beijing
Not applicable
160
Beijing
2025-11-30
Recruiting
Observational RegIstry of Effectiveness and Safety of teNecTeplase in reAl worLd Settings in China
NCT07271342Stroke
Beijing Tiantan Hospital
Observational
10,000
Beijing
2025-11-30
Not yet open
Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage
NCT07249853Aneurysmal Subarachnoid Hemorrhage
Beijing Tiantan Hospital
Phase 3
316
Beijing
2025-11-30
Recruiting
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
NCT07441291B ALL, Allogenetic Hematopoietic Stem Cell Transplantation, MRD-positive
Peking University People's Hospital
Phase 3
70
Beijing
2025-11-30
Not yet open
Rehabilitation Exercise Intervention for Rheumatoid Arthritis Patients Using Artificial Intelligence-Based Exercise Prescription System
NCT07246811Rheumatoid Arthritis (RA)
Peking University Third Hospital
Not applicable
147
Beijing
2025-11-30
Recruiting
A Phase โ…กa Clinical Study of CL-197 Capsules
NCT07308782HIV-1 Infection
Henan Genuine Biotech Co., Ltd.
Phase 2
24
Beijing
2025-11-29
Recruiting
The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management
NCT06909773Cardiovascular Diseases
AstraZeneca
Not applicable
3,000
Anqing, Beijing, Changsha, Chaohu, Chengdu, Chifeng, Chongqing, Dalian
2025-11-28
Recruiting
Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting
NCT07236814Influenza
Capital Medical University
Phase 3
384
Beijing
2025-11-28
Recruiting
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
NCT07220538Ischemic Stroke Hospitalized, Impairment, Cognitive
Dr. Willmar Schwabe GmbH & Co. KG
Phase 4
400
Anyang, Baotou, Beijing, Beipiao, Benxi, Chenzhou, Chifeng, Dalian
2025-11-28
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
NCT06994845Primary Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals
Phase 3
31
Hangzhou, Beijing
2025-11-27
Recruiting
A Phase โ… /โ…กa Clinical Study of GEN-725 in Combination With Dositinib
NCT07362940Non-Small Cell Lung Cancer
Henan Genuine Biotech Co., Ltd.
Phase 1/2
110
Beijing, Changsha, Jinan, Xiamen, Zhengzhou
2025-11-27
Recruiting
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
150
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Nanning, Shijiazhuang
2025-11-27
Recruiting
A Prediction Model in Pregnant Women With Aplastic Anemia
NCT07101770Aplastic Anemia, Pregnancy, Prediction Model
Peking University People's Hospital
Observational
300
Beijing
2025-11-27
Recruiting
YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)
NCT07793500NSCLC, Advanced Solid Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1
36
Beijing
2025-11-27
Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
NCT07236099Prurigo Nodularis (PN)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Jingzhou, Changsha
2025-11-27
Recruiting
Establishment of a Multimodal Standard Database for Inflammation-related Ophthalmopathy
NCT07628946Ocular Surface Disease, Inflammatory Disease, Retinal Disease, Choroid Diseases
Dan Chen
Observational
3,000
Beijing
2025-11-26
Recruiting
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
NCT07160608Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.
Phase 2
75
Baotou, Beijing, Guangzhou, Hangzhou, Nanchang, Shenzhen
2025-11-26
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO-resistant sqNSCLC
Takeda
Phase 3
600
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Xinxiang
2025-11-26
Active, closed
Effect of Perception-based Interventions on Public Acceptance of Using Large Language Models in Medicine
NCT07304908Large Language Models, Acceptability of Health Care, Perception, Self
Peking University
Not applicable
3,000
Beijing
2025-11-25
Recruiting
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT07155174Small Cell Lung Cancer
AbbVie
Phase 2
180
Beijing, Zhengzhou, Wuhan, Nanchang, Shanghai, Chengdu
2025-11-25
Not yet open
Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome
NCT07240376Non-Allergic Rhinitis With Eosinophilia Syndrome
Huazhong University of Science and Technology
Not applicable
90
Guangzhou, Wuhan, Xiangyang, Nanchang, Chengdu, Beijing, Shanghai
2025-11-25
Recruiting
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOYยฎ (US-Sourced YERVOYยฎ) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT07176650Hepatocellular Carcinoma (HCC)
Shanghai Henlius Biotech
Phase 1
246
Beijing, Bengbu, Changchun, Changsha, Chengdu, Dongguan, Fuzhou, Ganzhou
2025-11-25
Recruiting
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
NCT07355699Marginal Zone Lymphoma(MZL)
Beijing Tongren Hospital
Phase 4
88
Beijing
2025-11-25
Active, closed
A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis
NCT07136805Non-infectious Anterior Uveitis
VivaVision Biotech, Inc
Phase 3
154
Chongqing, Beijing
2025-11-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
Hoffmann-La Roche
Phase 3
900
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing
2025-11-24
Not yet open
Subthalamic Nucleus Versus Globus Pallidal Internus Deep Brain Stimulation for Parkinson Disease
NCT07250685PD - Parkinson's Disease
Zhang Jianguo
Not applicable
86
Beijing, Wuhan, Nanjing, Dalian, Jinan, Shanghai, Tianjin, Hangzhou
2025-11-24
Recruiting
A Phase Ia Clinical Trial of HW241045
NCT07448194Healthy Volunteers, IPF
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase 1
56
Beijing
2025-11-24
Recruiting
Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke
NCT07279493Acute Ischemic Stroke
Kunming Pharmaceuticals, Inc.
Phase 2
300
Beijing, Shenzhen, Cangzhou, Hengshui, Daqing, Anyang, Nanyang, Xuzhou
2025-11-22
Active, closed
Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A
NCT07229807Influenza a
Guangdong Raynovent Biotech Co., Ltd
Phase 3
119
Beijing
2025-11-22
Recruiting
Effect of Visual-Guided Balance Training on Knee Motor Function and Biomechanical Characteristics After ACL Reconstruction
NCT07306221Anterior Cruciate Ligament Injuries
Peking University Third Hospital
Not applicable
45
Beijing
2025-11-22
Recruiting
A Platform Study of In Vivo CAR-T for Treating Advanced Malignant Tumors Based on Target Screening
NCT07395479Advanced Malignant Tumours
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1
50
Beijing
2025-11-21
Recruiting
A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
NCT07208058Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
TJ Biopharma Co., Ltd.
Phase 3
30
Beijing, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Nanchang, Shenyang
2025-11-21
Recruiting
Asymptomatic TB With Innovative Modified Short-course Regimens
NCT06153069Tuberculosis
Huashan Hospital
Phase 4
426
Beijing, Liupanshui, Nayong, Shanghai, Hangzhou
2025-11-21
Recruiting
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
NCT07650084Refractory Chronic Cough
GlaxoSmithKline
Phase 3
75
Leshan, Beijing, Changsha, Chengdu, Chongqing, Dongguan, Ganzhou, Guangzhou
2025-11-21
Recruiting
Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
NCT07371923Diffuse Large B Cell Lymphoma (DLBCL)
Beijing Tongren Hospital
Phase 2
50
Beijing
2025-11-20
Not yet open
Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients
NCT06683131Acute Myocardial Infarction (AMI)
The Affiliated Hospital of Xuzhou Medical University
Phase 4
1,160
Fuyang, Huai'an, Lianyungang, Nanjing, Suqian, Xuzhou, Beijing, Shanghai
2025-11-20
Recruiting
A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors
NCT07253116Advanced Solid Tumors
Nanjing Jingao biomidical technology Co. Ltd.
Phase 1/2
20
Beijing
2025-11-20
Recruiting
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
NCT07216027Atopic Dermatitis, Eczema, Atopic
Pfizer
Phase 2
165
Shanghai, Beijing
2025-11-20
Recruiting
Neuroendoscopy-assisted Drainage Versus Burr Hole Drainage for Chronic Subdural Hematoma
NCT07144423Chronic Subdural Hematoma
Beijing Tiantan Hospital
Not applicable
770
Beijing, Xiamen, Jiangmen, Shantou, Shenzhen, Liuzhou, Nanning, Wuzhou
2025-11-19
Active, closed
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685Alport Syndrome
Bayer
Phase 2
60
Beijing, Chongqing, Guangzhou, Wuhan, Hangzhou
2025-11-19
Recruiting
The Feasibility Study of Polymer Artificial Heart Valve for the Treatment the Mitral Valve Disease.
NCT07243184Severe Mitral Valve Regurgitation, Severe Mitral Valve Stenosis
Shanghai HeartEpoch Medical Technology Co., Ltd
Not applicable
10
Beijing
2025-11-19
Active, closed
Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study
NCT07216976Parkinson's Disease
MedtronicNeuro
Not applicable
61
Beijing, Guangzhou, Shanghai, Chengdu
2025-11-19
Recruiting
A Phase 1 Study of HDM2017 in Advanced Solid Tumors
NCT07274085Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
96
Beijing
2025-11-18
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07228832Metastatic Colorectal Cancer (CRC)
Summit Therapeutics
Phase 3
600
Beijing, Fuzhou, Guangzhou, Foshan, Shenzhen, Haikou, Shijiazhuang, Harbin
2025-11-18
Recruiting
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
NCT07243171Overweight and/or Obesity, Weight Management
Hangzhou Sciwind Biosciences Co., Ltd.
Phase 1/2
126
Beijing
2025-11-18
Recruiting
Efficacy and Safety of Subcutaneous Injection of XH-02 in the Treatment of Adult Hypoparathyroidism
NCT07530705Hypoparathyroidism
Peking Union Medical College Hospital
Phase 1/2
15
Beijing
2025-11-17
Recruiting
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
NCT07161388Limited Stage Small-Cell Lung Cancer
AstraZeneca
Observational
200
Beijing, Cangzhou, Dongguan, Fuzhou, Guangzhou, Huzhou, Jinan, Nanjing
2025-11-17
Recruiting
Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection
NCT07128888Obesity or Overweight
Gan & Lee Pharmaceuticals.
Phase 1
60
Beijing
2025-11-17
Recruiting
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia
NCT07231120Cachexia-Anorexia Syndrome, Solid Tumor Malignancies
Jiangsu Nutai Biologics Co., Ltd
Phase 1
54
Beijing
2025-11-17
Recruiting
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
NCT07290803Atopic Dermatitis
Sanofi
Observational
1,000
Beijing, Shenzhen, Changsha, Xiโ€™an, Chengdu, Hangzhou, Ningbo, Chongqing
2025-11-17
By invitation
Clinical Evaluation of [68Ga]Ga-NOTA-RF PET Imaging Targeting RFVT3 in Patients With Pituitary Tumors
NCT07254104Pituitary Neoplasms
Peking Union Medical College Hospital
Phase EARLY_PHASE1
30
Beijing
2025-11-17
Recruiting
Weekly Dynamics of Psychopathological and Symptom Networks During Mindfulness-Based Interventions for Emotional Distress
NCT07280481Depression, Anxiety, Emotional Disorders
Peking University
Not applicable
500
Beijing
2025-11-16
Recruiting
Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)
NCT07439133Coronary Artery Disease(CAD)
Sinotau Pharmaceutical Group
Phase 3
395
Beijing, Foshan, Tianjin
2025-11-14
Recruiting
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
NCT07209813Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
Beijing Gene Key Life Technology Co., Ltd
Phase 2
48
Beijing, Zhengzhou, Changsha, Nanjing, Nanchang, Hangzhou
2025-11-14
Recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420Palmoplantar Pustulosis
UCB Biopharma SRL
Phase 3
320
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Shenzhen
2025-11-14
Recruiting
Registry Study of Cerebral Small Vessel Disease
NCT07342075Cerebral Small Vessel Diseases, Cognitive Impairment, Diffusion Tensor Imaging
Dongzhimen Hospital, Beijing
Observational
50
Beijing
2025-11-13
Recruiting
A Study of DEG6498 in Participants With Solid Tumors
NCT07244835Malignant Neoplasms
Degron Therapeutics Co.
Phase 1
100
Beijing, Guangzhou
2025-11-13
Recruiting
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
NCT07239245Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing, Zhengzhou, Shenyang, Taiyuan
2025-11-12
Recruiting
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
NCT07207070Breast Cancer
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
312
Beijing, Zhengzhou
2025-11-12
Not yet open
Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid
NCT07210554Bullous Pemphigoid (BP)
Chengdu Kangnuoxing Biopharma,Inc.
Phase 3
200
Beijing
2025-11-11
Recruiting
Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.
NCT07423013Thyroid Eye Disease
Peking University Third Hospital
Not applicable
50
Beijing
2025-11-11
Recruiting
Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke
NCT07290751Acute Ischemic Stroke
Beijing Anzhen Hospital
Phase 4
976
Beijing
2025-11-11
Recruiting
Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
NCT07232654LOCALLY ADVANCED CERVICAL CANCERS
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2025-11-11
Recruiting
Real-world Study of Aflibercept 8 mg in nAMD
NCT07640997Neovascular Age-Related Macular Degeneration (nAMD)
Peking University People's Hospital
Observational
300
Beijing, Fuzhou, Shenzhen, Zunyi, Harbin, Nanyang, Wuhan, Hohhot
2025-11-11
Recruiting
Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL
NCT07175662High-grade Squamous Intraepithelial Lesion (HSIL)
Newish Biotech (Wuxi) Co., Ltd.
Phase 2
150
Beijing, Taiyuan
2025-11-11
Recruiting
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
NCT07215585Large B-cell Lymphoma
AstraZeneca
Phase 3
420
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hefei
2025-11-11
Recruiting
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
NCT07168161ANCA Associated Vasculitis (AAV)
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase 3
300
Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Meizhou, Shaoguan, Shenzhen
2025-11-10
Recruiting
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
NCT07181681Solid Tumors, Advanced Solid Tumor
BeOne Medicines
Phase 1
63
Beijing, Chongqing, Xiamen, Zhengzhou, Shanghai, Chengdu, Hangzhou
2025-11-10
Recruiting
A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)
NCT07261644Ankylosing Spondylitis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
500
Beijing
2025-11-07
Recruiting
A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
NCT07265921Advanced Solid Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
232
Beijing, Nanjing, Shanghai, Tianjin, Wuhan
2025-11-07
Recruiting
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
NCT06902740Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque
Peking Union Medical College Hospital
Phase 4
300
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2025-11-07
Recruiting
Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naรฏve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)
NCT07711223Infection, Human Immunodeficiency Virus
Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Phase 1/2
660
Beijing
2025-11-07
Recruiting
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
NCT07361094Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis, Relapsed/Refractory Idiopathic Inflammatory Myopathies, Relapsed/Refractory sjรถgren's Syndrome
Beijing Boren Hospital
Phase 1
12
Beijing
2025-11-06
Recruiting
Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
NCT07110415Coronary Heart Disease, Cardiac Dysfunction
SPH Qingdao Growful Pharmacetical Co.,Ltd
Phase 4
2,708
Haozhou, Beijing, Chongqing, Lanzhou, Guangzhou, Shantou, Zhuhai, Guilin
2025-11-06
Recruiting
A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray
NCT07259538Chronic Rhinosinusitis (CRS)
VivaVision Biotech, Inc
Phase 1
60
Beijing
2025-11-06
Active, closed
A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection
NCT07245953Chronic Hepatitis B
Suzhou HepaThera Biotech Co., Ltd.
Phase 2
60
Beijing, Fuzhou, Guangzhou, Qingyuan, Nanning, Zhengzhou, Nanjing, Zhenjiang
2025-11-05
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 2/3
500
Beijing, Chongqing, Fuzhou, Jiangmen, Anyang, Luoyang, Jingzhou, Wuhan
2025-11-05
Recruiting
Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
NCT07315854Gastric Cancer (GC), Gastroesophageal Junction Cancer, Advanced Gastric Cancer, Metastatic Gastric Cancer
Beijing Friendship Hospital
Phase 2
32
Beijing
2025-11-04
Recruiting
IBI351 Plus Cetuximab ฮฒ in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NCT07198841Lung Cancer (Non-Small Cell)
Guangdong Association of Clinical Trials
Phase 2
48
Guangzhou, Beijing, Foshan, Nanchang, Nanning, Shijiazhuang
2025-11-03
Recruiting
Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques
NCT06855537Coronary Arterial Disease (CAD), Vulnerable Coronary Plaques, Thin-cap fIbroatheroma, Acute Coronary Syndromes (ACS)
Beijing Anzhen Hospital
Phase 4
2,190
Beijing
2025-11-03
Recruiting
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
NCT07223840Smoking
Eli Lilly and Company
Phase 2
222
Beijing, Chengdu, Chongqing, Hangzhou, Linhai, Ningbo, Shenzhen
2025-11-03
Recruiting
Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China
NCT07143149Ischemic Stroke, Transient Ischemic Attack (TIA)
Beijing Tiantan Hospital
Not applicable
4,000
Beijing
2025-11-03
Recruiting
RCT of Tocilizumab for Anti-MDA5+DM
NCT07377058Dermatomyositis
Peking Union Medical College Hospital
Not applicable
110
Beijing
2025-11-01
Recruiting
A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.
NCT06641648Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Relapse, NK Cell
Peking University First Hospital
Phase 1
12
Beijing
2025-11-01
Recruiting
TAIC FOLFOX for Locally Advanced G/GEJA
NCT07655024Gastric Cancer (Diagnosis), Gastroesophageal Junction Adenocarcinoma
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Phase 2
31
Beijing
2025-11-01
By invitation
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy๏ผˆnCT๏ผ‰ in the Treatment of Esophageal Squamous Cell Carcinoma
NCT07312578Esophageal Squamous Cell Carcinoma
Peking University
Phase 2
48
Beijing
2025-11-01
Recruiting
An Exploratory Research on the Efficacy and Safety of Antibacterial Absorbable Dressing in Chronic Non-healing Wounds
NCT07261501Wound Heal, Wound Healing Delayed
Peking University Third Hospital
Not applicable
30
Beijing
2025-11-01
Recruiting
CAIX PET/ CT Guided Radiation Therapy in CcRCC.
NCT07540260Radiation Therapy, Metastatic Renal Cancer, Recurrent Renal Cell Cancer
Peking University First Hospital
Not applicable
70
Beijing
2025-11-01
Recruiting
One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei
NCT07328737Pseudomyxoma Peritonei
Beijing Tsinghua Chang Gung Hospital
Not applicable
132
Beijing
2025-11-01
By invitation
Retrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis
NCT07373951Non-Small Cell Lung Cancer, Brain Metastases
Ming Yang
Observational
380
Beijing
2025-11-01
Recruiting
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
NCT07187440Fabry Disease
Takeda
Observational
200
Hefei, Beijing, Fuzhou, Hangzhou, Shantou, Shenzhen, Shijiazhuang, Harbin
2025-11-01
Rows per page Showing 1401–1500 of 5484
Previous 13 14 15 16 17 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=15

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.